A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Inclusion Criteria

* Provision of informed consent prior to any study specific procedures
* Histologic or cytologic diagnosis of advanced NSCLC, excluding large cell neuroendocrine, and mixed NSCLC/small-cell histologies
* Failure of one prior platinum-based doublet treatment for advanced NSCLC (either due to progressive disease or toxicity)
* Measurable disease as measured by Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* Mandatory availability of tumour tissue (archival or fresh if archival is not available) for TP53 testing
* Male or female ≥18 years-of-age
* Subjects may have received radiation for palliation prior to starting study treatment if they have recovered from the side effects of such therapy
* Absolute neutrophil count (ANC) ≥1500/μL
* Haemoglobin (Hgb) ≥9 g/dL
* Platelets ≥100,000/uL
* Adequate liver function defined as:
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits (WNL) or ≤2.5 x upper limit of normal (ULN), if liver metastases are present
* Serum bilirubin WNL
* Adequate renal function
* Ability to swallow oral medication
* Fertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops
* Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures
* Predicted life expectancy ≥12 weeks
* Willingness and ability to comply with study and follow-up procedures
* Ability to understand the investigational nature of this study and give written informed consent
* Most recent chemotherapy ≤21 days or have not recovered from the side effects \> Grade 1.
* Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of AZD1775
* Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting AZD1775 or has not recovered from side effects of such therapy
* Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures ≤7 days
* Known central nervous system (CNS) disease
* Any known hypersensitivity or contraindication to the components of study treatment (AZD1775 and docetaxel)
* Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association \[NYHA\] ≥ Class 2
* Pregnant or lactating
* Concurrent administration of medications or foods that are strong inhibitors of
* Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the subject to receive protocol treatment
* Presence of other active cancers, or history of treatment for invasive cancer ≤3 years
* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol